



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Charles R. Ashby Jr. Examiner: Lewis, Amy A.
Serial No.: 10/776,108 Group Art Unit: 1614
Filed: February 10, 2004 Confirmation No.: 2666
For: The Use of Vitamin B₆ To Mitigate Visual Field Defects
Associated With The Use Of GABAergic Drugs In Mammals

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TERMINAL DISCLAIMER

1. Identification of Person Making this Disclaimer (Disclaimant)

I,
represent that I am

- ☐ an inventor of this invention.
- ☐ an assignee of this invention.
- ☐ a representative authorized to sign on behalf of the assignee identified below.
- ☒ an attorney of record for this invention.

2. Identity of Assignee

The assignee of this invention is: Brookhaven Science Associates, having an address at:
P.O. Box 5000, Upton, New York 11793-5000.

3. Extent of Disclaimant's Interest

The extent of the interest in this invention that the disclaimant owns or represents is in:
☒ the whole of the invention.
☐ a sectional interest in this invention, as follows:

4. Recordation of Assignment in USPTO

- ☒ An assignment of the above-identified interest was recorded in the USPTO on 3/17/2003 at Reel .014118; Frame 0398.
- ☐ Authorization for recordation of an assignment of the above-identified interest is attached hereto, together with a separate assignment document cover sheet (Form PTO 1595).

5. Establishing Right of Assignee to Take Action

- ☐ Attached is a Certificate Under 37 CFR 3.73(b) establishing the right of the assignee to take action in this case.

6. Disclaimer

The terminal part of the statutory term of any patent granted on the present application identified above, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173 of:

- ☒ United States Patent No. 6,713,497 as presently shortened by any terminal disclaimer,
☐ Any patent granted on Application Serial No.

is hereby disclaimed, except as provided below, and it is agreed that any patent so granted on the present application shall be enforceable only for, and during, such period that the legal title to the patent granted on the present application shall be the same as the legal title to the specified patent, this agreement to run with any patent granted on the present application and to be binding upon the grantee, its successors, and assigns.

In making the above disclaimer, disclaimant does not disclaim the terminal part of any patent granted on the present application that would extend beyond the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the patent specified herein in the event that the latter patent later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or is terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued in any matter, or is terminated prior to expiration of its full statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title identified above.

7. Fee status

A fee is due under 37 CFR 1.20(d):

- ☐ Other than a small entity--fee \$110.00.
☒ Small entity--fee \$55.00.

8. Fee Payment

☐ Attached is a check in the sum of \$.


☒ Charge Account No. 02-3977 the sum of \$ 55.00.
A duplicate of this transmittal is attached.

Please charge Deposit Account 02-3977 for any deficiency, or credit same for any overpayment.

9. Declaration

☒ As I am not a person registered to practice before the Office, I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: July 31, 2006



Christine L. Brakel, Ph.D.
Patent Agent
Brookhaven National Laboratory
Reg. No. 45,772